Health Care & Life Sciences » Pharmaceuticals | Gemphire Therapeutics Inc.

Gemphire Therapeutics Inc.

Gemphire Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.42
Market Cap
$10.84 M
Shares Outstanding
14.27 M
Public Float
10.22 M

Profile

Address
17199 North Laurel Park Drive
Livonia Michigan 48152
United States
Employees -
Website http://www.gemphire.com
Updated 07/08/2019
Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the provision of treatment options for cardiometabolic diseases including dyslipidemia and NASH. It offers a small molecule formulated as a tablet product under the Gemcabene brand.

Financials

View All
Created with Highcharts 5.0.14Gemphire Therapeutics Inc.Net Income. Fiscal year is January-December. All values USD Thousands.32032010 07610 07614 58614 58633 41533 41523 63723 63720142015201620172018010k20k30k40k

Charles L. Bisgaier
Chairman & Chief Scientific Officer
Steven R. Gullans
President, Chief Executive Officer & Director